Skip to main content
European Commission logo print header

Demonstration of the clinical utility of holotc as an early marker of vitamin b12 deficiency

Objective

Vitamin B12 deficiency occurs in 10% of the elderly (10 million in EU) and is associated with psychiatric morbidity (dementia and depression), costing EU many billions of ecru/year. Treatment is inexpensive and effective but identification of those needing therapy is hampered by the poor diagnostic accuracy of conventional tests. A European company has developed an assay to measure holotranscobalamin (helot), a sensitive marker of early B12 deficiency. The aims of the project are to demonstrate the analytical performance of this assay in 4 countries; to show its superiority to conventional methods for assessment of vitamin B12 status; and to demonstrate its value in older patients with depression or dementia. Socio-economic benefits will be: identification and early treatment of persons with B12-related morbidity; improved health economy, and promotion of European industry in laboratory diagnostics.

Call for proposal

Data not available

Coordinator

AARHUS KOMMUNEHOSPITAL - AARHUS UNIVERSITY HOSPITAL
Address
Noerreborgade 44
8000 Aarhus c
Denmark

See on map

EU contribution
€ 0,00

Participants (4)